RAPT Therapeutics, Inc. (NASDAQ: RAPT)

RAPT Therapeutics, Inc. (NASDAQ: RAPT), a clinical-stage biopharmaceutical company, is dedicated to discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. The company's proprietary drug discovery and development engine facilitates the identification of therapeutic targets and the design of selective small molecules that modulate critical immune responses.

RAPT Therapeutics' main business activities revolve around the development of oral small molecule therapies. The company operates in the biopharmaceutical industry, specifically focusing on inflammatory diseases and oncology. Its operations span across various countries, with a strong presence in the United States.

The company generates revenue through the development and commercialization of its drug candidates. Its primary products include zelnecirnon (RPT193) and tivumecirnon (FLX475). Zelnecirnon is a CCR4 antagonist designed to selectively inhibit the migration of Th2 cells into inflamed tissues, demonstrating promising results in Phase 1b clinical trials. It is being developed to treat various inflammatory diseases, including atopic dermatitis, asthma, chronic obstructive pulmonary disease, chronic spontaneous urticaria, alopecia areata, prurigo nodularis, chronic rhinosinusitis with nasal polyps, allergic rhinitis, and eosinophilic esophagitis.

On the other hand, tivumecirnon is also a CCR4 antagonist, but it is designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors. It has shown encouraging results in Phase 2 clinical trials, demonstrating clinical activity as monotherapy and in combination with the programmed cell death (PD-1) checkpoint inhibitor pembrolizumab in patients with advanced cancer.

RAPT Therapeutics holds a strong position within the industry, boasting a proprietary drug discovery and development engine as one of its key competitive advantages. This engine enables the identification of therapeutic targets and the design of selective small molecules that modulate critical immune responses. Additionally, the company has a strong team with deep expertise in immunology and drug discovery, further supported by extensive capabilities in computational sciences.

The company's customers include patients with inflammatory diseases and cancer, as well as healthcare providers and payers. RAPT Therapeutics is committed to delivering innovative and effective therapies that improve patient outcomes and quality of life.

The brand names and/or trade names of its products include zelnecirnon (RPT193) and tivumecirnon (FLX475). These drug candidates represent the company's commitment to developing innovative and effective therapies for patients with significant unmet needs in inflammatory diseases and oncology.